Efficacy of Broad-Band Ultraviolet B versus Vitamin D3 supplementation in balance control and cognitive functions in Patients with Multiple Sclerosis

Somatic and Cognitive impacts of Broad-Band Ultraviolet B Radiation versus Vitamin D3 supplementation in Patients with Relapsing-Remitting Multiple Sclerosis.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201801002891127

Enrollment

Registered

2017-12-19

Start date

2017-12-04

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases Multiple Sclerosis Relapsing-Remitting Type

Interventions

Broad Band Ultraviolet B Radiation (BB-UVBR)

Vitamin D3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: During remission state, after at least one year of disease duration since MS established diagnosis. EDSS less than or equal to 5.5. BMI less than or equal to 35. Depression free patients according to DSM 5 criteria of depressive disorders (Diagnostic and Statistical Manual of Mental Disorders) (APA, 2013). Patients with intact visual field only. Patients Free from any systemic vascular or blood disease, vasculitis, diabetes, liver disease, kidney failure, heart failure, traumatic brain injury (TBI), cerebrovascular accident (CVA), spinal cord injury, human immunosuppressive virus (HIV), hyperthyrodism, cancer or at risk of chemical or atomic radiation exposure. Patients who are controlled by (interferon beta-1a) therapy only. Patients who are consuming, antibiotics or any photosensitizing drugs will be weaned off of it for 21-30 days before joining the study.

Exclusion criteria

Exclusion criteria: Patient passing into an MS relapse during the study period. Female patients who get pregnant during the study period. Patients on Hypolipidemic, Antiepileptic drugs.

Design outcomes

Primary

Measure	Time frame
Dynamic Balance, will be tested using Biodex Balance System (BBS):- (Overall stability index (OSI), Anterior/Posterior stability index (AP), Medial/Lateral stability index (ML). ;Cognitive functions, will be tested using:- i. MoCA "Montreal Cognitive Assessment" (Rahman and EL Gaafary, 2009). ii. SDMT "Symbol Digit Modalities Test" (Smith, 1991). iii. BVMT- R "Brief Visuospatial Memory Test - Revised" (Benedict, 1997). iv. Fatigue Severity Scale (FSS) (Al-Sobayel et al, 2016).	—

Measure

Time frame

Dynamic Balance, will be tested using Biodex Balance System (BBS):- (Overall stability index (OSI), Anterior/Posterior stability index (AP), Medial/Lateral stability index (ML). ;Cognitive functions, will be tested using:- i. MoCA "Montreal Cognitive Assessment" (Rahman and EL Gaafary, 2009). ii. SDMT "Symbol Digit Modalities Test" (Smith, 1991). iii. BVMT- R "Brief Visuospatial Memory Test - Revised" (Benedict, 1997). iv. Fatigue Severity Scale (FSS) (Al-Sobayel et al, 2016).

—

Secondary

Measure	Time frame
Serum 25(OH) D. Using Hematology test.;Serum Neurofilament Light chain (sNFL). Using Hematology test.	—

Countries

Egypt

Contacts

Public ContactDalia Mossad

Ass. Prof, PT/ Faculty of Physical Therapy , Cairo University

drdaliamosaad@gmail.com00201148939556

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026